# GLP-1s for $50 a Month? 14 Million Medicare Recipients May Be Eligible
Up to 14 million Medicare beneficiaries now qualify for GLP-1 receptor agonists at a $50 monthly copay through expanded Medicare coverage. This change opens access to weight-loss and diabetes medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) for seniors who previously faced prohibitive out-of-pocket costs.
The expansion targets Medicare Part D enrollees with type 2 diabetes or obesity. Beneficiaries must meet specific eligibility criteria, including having a BMI of 30 or higher or diagnosed obesity-related conditions. The $50 cap applies to covered GLP-1 medications, making these drugs substantially more affordable than their typical retail prices, which can exceed $900 monthly.
Medicare negotiated these lower prices under provisions of the Inflation Reduction Act. The negotiation process focused on reducing costs for high-demand medications while maintaining access. For seniors managing both weight and blood sugar, GLP-1s offer dual benefits. Research shows these medications improve cardiovascular outcomes and reduce mortality risk in people with diabetes.
However, access remains conditional on plan enrollment. Medicare Part D plans vary in their coverage formulations. Some plans may require prior authorization or step therapy, meaning patients try other medications first. Beneficiaries should review their specific plan details during annual enrollment periods to confirm GLP-1 coverage and cost structures.
The $50 copay represents a landmark shift in medication accessibility for older Americans. Seniors paying full price previously rationed doses or skipped medications entirely due to cost. This pricing removes a significant barrier for the roughly 10 million Medicare beneficiaries with type 2 diabetes and the millions more living with obesity.